Longevity Startup to Conduct Human Trials for Anti-Aging Gene Therapy
Life Biosciences, a Boston-based biotech company founded by Harvard professor David Sinclair, is set to begin human clinical trials for a cellular reprogramming treatment targeting aging.
The treatment aims to rejuvenate cells without altering their core function, potentially addressing age-related diseases such as Alzheimer's, Type 2 diabetes, and Parkinson's.
This potential breakthrough for longevity science also raises a host of ethical concerns, from overpopulation to "hyper-beautification."
The company's mission is to develop a therapy that can turn back the clock on aging, and if successful, could have a significant impact on human health.
Author's Summary
Life Biosciences is pioneering human trials for anti-aging gene therapy.